AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails - Zacks.com

AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails  Zacks.com

IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.



Comments

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Oncology: The disease, dynamics & challenges of market research

Division of Continuing Professional Development